Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
14 Fevereiro 2024 - 6:30PM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage clinical
biopharmaceutical company, today announced that it will release its
fourth quarter and full-year 2023 financial results and business
highlights before the market opens on Wednesday, February 28, 2024
via press release, which will be available on the Company’s website
at www.geron.com/investors. Geron will host a conference call to
discuss the financial results as well as business highlights at
8:00 a.m. ET the same day.
A live webcast of the conference call and related presentation
will be available on the Company’s website at
www.geron.com/investors/events. An archive of the webcast will be
available on the Company’s website for 30 days.
Participants may access the webcast by registering online using
the following link,
https://events.q4inc.com/attendee/964382933
About Geron
Geron is a late-stage clinical biopharmaceutical company
pursuing therapies with the potential to extend and enrich the
lives of patients living with hematologic malignancies. Our
first-in-class investigational telomerase inhibitor, imetelstat,
harnesses Nobel Prize-winning science in a treatment that may alter
the underlying drivers of disease. The New Drug Application (NDA)
for imetelstat for the treatment of transfusion dependent anemia in
patients with lower-risk myelodysplastic syndromes (LR-MDS) who
have failed to respond or have lost response to or are ineligible
for erythropoiesis-stimulating agents (ESAs), based on the results
from the Phase 3 IMerge clinical trial, is currently under review
by the United States Food and Drug Administration (FDA) with a
Prescription Drug User Fee Act (PDUFA) target action date of June
16, 2024. In addition, an MAA is under review in the European Union
for the same proposed indication. Furthermore, Geron currently has
an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in
relapsed/refractory myelofibrosis (R/R MF). To learn more, visit
www.geron.com or follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240214669884/en/
Aron Feingold Vice President, Investor Relations and Corporate
Communications
Kristen Kelleher Senior Manager, Investor Relations
investor@geron.com media@geron.com
Geron (NASDAQ:GERN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Geron (NASDAQ:GERN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024